The Central Drugs Standard Control Organisation (CDSCO) has identified 330 drug samples as Not of Standard Quality (NSQ) and one spurious drug sample during its routine regulatory surveillance for September 2026, The Hindu BusinessLine and ANI reported on October 23.

Source: The Hindu BusinessLine (ANI)

According to the monthly report, Central Drugs Laboratories identified 42 drug samples as NSQ, while State Drugs Testing Laboratories identified 288 such samples. Medical Dialogues reported that the 42 central-laboratory failures covered tablets, capsules, injections, intravenous fluids, syrups and surgical products, with failures on parameters including assay, dissolution, sterility and pH.

Source: Medical Dialogues

A sample is declared NSQ when it fails one or more specified quality parameters. CDSCO clarified that the failure is specific to the drug products belonging to the batch tested by the government laboratory and does not warrant concerns about other drug products available in the market, ANI reported via LatestLY.

Source: ANI via LatestLY

The one spurious sample, from the National Capital Territory of Delhi, was manufactured by unauthorised manufacturers using a brand name owned by another company, according to the report. The matter is under investigation and action will be taken as per the applicable Act and Rules.

Source: The Hindu BusinessLine (ANI)

CDSCO said the identification of NSQ and spurious medicines is carried out regularly in collaboration with state regulators to ensure such drugs are identified and removed from the market. In August, the regulator had identified 220 NSQ samples — 29 by central laboratories and 191 by state laboratories — and one spurious sample, also in Delhi.

Source: ANI via LatestLY